- Home
- AUPH vs PHVS Comparison
AUPH vs PHVS Comparison
Compare AUPH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- PHVS
- Stock Information
- Founded
- AUPH 1993
- PHVS 2015
- Country
- AUPH Canada
- PHVS Netherlands
- Employees
- AUPH N/A
- PHVS N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- PHVS Health Care
- Exchange
- AUPH Nasdaq
- PHVS Nasdaq
- Market Cap
- AUPH 1.3B
- PHVS 1.0B
- IPO Year
- AUPH 1999
- PHVS 2021
- Fundamental
- Price
- AUPH $8.01
- PHVS $18.36
- Analyst Decision
- AUPH Strong Buy
- PHVS Strong Buy
- Analyst Count
- AUPH 3
- PHVS 5
- Target Price
- AUPH $10.33
- PHVS $40.60
- AVG Volume (30 Days)
- AUPH 1.4M
- PHVS 47.5K
- Earning Date
- AUPH 02-13-2025
- PHVS 11-13-2024
- Dividend Yield
- AUPH N/A
- PHVS N/A
- EPS Growth
- AUPH N/A
- PHVS N/A
- EPS
- AUPH N/A
- PHVS N/A
- Revenue
- AUPH $220,361,000.00
- PHVS N/A
- Revenue This Year
- AUPH $36.97
- PHVS N/A
- Revenue Next Year
- AUPH $16.43
- PHVS N/A
- P/E Ratio
- AUPH N/A
- PHVS N/A
- Revenue Growth
- AUPH 38.72
- PHVS N/A
- 52 Week Low
- AUPH $4.71
- PHVS $15.21
- 52 Week High
- AUPH $10.67
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- AUPH 40.52
- PHVS 48.93
- Support Level
- AUPH $7.60
- PHVS $15.21
- Resistance Level
- AUPH $9.31
- PHVS $19.59
- Average True Range (ATR)
- AUPH 0.32
- PHVS 1.39
- MACD
- AUPH -0.12
- PHVS -0.02
- Stochastic Oscillator
- AUPH 27.45
- PHVS 67.31
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.